Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Offer $325M in Convertible Notes; Will Use $200M to Repurchase Shares

NEW YORK (GenomeWeb News) - Illumina plans to sell $325 million in convertible senior notes pay for corporate expenses, the company said today.
Illumina said it will use roughly $200 million of the proceeds to buy shares of its common stock in a private transaction, and some of the rest will go to pay the cost of the convertible transactions.
The notes will be due 2014 and upon conversion holders will receive cash value for the principal amount and any excess will be given in common stock.
Any remaining balance will go to general corporate purposes, which the company said could include acquisitions or more purchases of its own stock.
Illumina said the interest rate and other terms have yet to be negotiated.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.